Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis

ConclusionIn this analysis of   >  1000 patients treated with DRF in real-world clinical practice, overall persistence at 16 months was high, treatment discontinuation due to GI AEs was low, and patients were highly adherent to therapy. Of 433 patients who switched from DMF to DRF, most (>  90%) were able to tolerate and persist on DRF after switching.Graphical abstract available for this article.Graphical Abstract
Source: Neurology and Therapy - Category: Neurology Source Type: research